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Abstract
Introduction: South Africa has the largest number of individuals living with HIV and the largest antiretroviral therapy (ART)
programme worldwide. In September 2016, ART eligibility was extended to all 7.1 million HIV-positive South Africans. To
ensure that further expansion of services does not compromise quality of care, long-term outcomes must be monitored. Few
studies have reported long-term mortality in resource-constrained settings, where mortality ascertainment is challenging.
Combining site records with data linked to the national vital registration system, sites in the International Epidemiology
Databases to Evaluate AIDS Southern Africa collaboration can identify >95% of deaths in patients with civil identification
numbers (IDs). This study used linked data to explore long-term mortality and viral suppression among adults starting ART in
South Africa.
Methods: The study was a cohort analysis of routine data on adults with IDs starting ART 2004–2015 in five large ART
cohorts. Mortality was estimated overall and by gender using the Kaplan-Meier estimator and Cox’s proportional hazards
regression. Standardized mortality ratios (SMRs) were calculated by dividing observed numbers of deaths by numbers
expected if patients had been HIV-negative. Viral suppression in patients with viral loads (VLs) in their last year of follow-
up was the secondary outcome.
Results: Among 72,812 adults followed for 350,376 person years (pyrs), the crude mortality rate was 3.08 (95% CI 3.02–
3.14)/100 pyrs. Patients were predominantly female (67%) and the percentage of men initiating ART did not increase.
Cumulative mortality 12 years after ART initiation was 23.9% (33.4% male and 19.4% female). Mortality peaked in patients
enrolling in 2007–2009 and was higher in men than women at all durations. Observed mortality rates were higher than HIV-
negative mortality, decreasing with duration. By 48 months, observed mortality was close to that in the HIV-negative
population, and SMRs were similar for all baseline CD4 strata. Three-quarters of patients had VLs in their last year, and 86%
of these were virally suppressed.
Conclusions: The South African ART programme has shown a remarkable ability to initiate and manage patients successfully
over 12 years, despite rapid expansion. With further scale-up, testing and initiating men on ART must be a national priority.
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Introduction
The rate of scale-up of ART services in developing countries
has increased dramatically in recent years. By the end of
2015, 17 million people globally received ART, including 12
million individuals living with HIV in sub-Saharan Africa [1].
South Africa has both the largest number of individuals
living with HIV and the largest ART programme worldwide.
By mid-2015, 11 years after the inception of the pro-
gramme, an estimated 3.39 million individuals were on
ART [2]. In September 2016, South Africa implemented
universal ART eligibility, extending ART eligibility to all 7.1
million HIV-positive South Africans. While the benefits of
universal HIV treatment are evident, concerns that further
expansion of ART programmes may compromise quality of
care [3–7] make it essential to monitor trends in the mor-
tality of patients on ART.
To date, few studies have reported long-term mortality in
ART programmes in resource-constrained settings [3,8–10].
Using routine data captured by sites, we have previously
reported decreasing mortality in the first year of ART in
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successive calendar years of ART initiation [11]. Such appar-
ent declines in mortality may be real or could be due to
deteriorating mortality ascertainment and retention in
rapidly expanding ART programmes [12,13]. Indeed, as
access to ART has expanded, routine data have increasingly
underestimated true mortality: the proportion of deaths
recorded in South African ART programmes dropped from
60% to 30% (2004–2005 compared with 2010
onwards) [13].
One innovative way of improving mortality ascertainment is
through linkage of site records to vital registration systems. In
South Africa, the National Population Register (NPR) records
deaths of individuals with IDs and is estimated to be around
94% complete for adult deaths [13]. The inclusion of linkage
data doubled cumulative all-cause mortality at four years after
ART initiation in a large public sector programme in Cape Town
[14], highlighting the need for accurate, recent and long-term
mortality data [15]. The International Epidemiology Databases
to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration is
uniquely placed to provide such estimates [16]. Combining site
recordswith linkage data, sites participating in the collaboration
can identify over 95% of deaths in patients with South African
IDs [13].
Gender differences in mortality have been reported bymany
large ART programmes across Africa [17–22]. While most
researchers have attributed men’s elevated mortality risk to
their own poorer health-seeking behaviour, we have previously
found that the observed differences inmortality on ARTmay be
best explained by background differences in death rates, unre-
lated to HIV/AIDS [23]. Givenmen’s poorer access to HIV testing
and treatment [23–28] and outcomes on treatment across Sub-
Saharan Africa [17–23,29–32], long-term outcome data must
also be explored by gender.
Whereas preventing HIV-associated mortality and morbidity
has long been the major focus of ART programmes in high
burden settings, one of the rationales for the recent change
to universal access to ART is the impact of widespread viral
suppression on HIV transmission. South Africa is one of the few
high burden settings where routine viral load (VL) testing is
available, enabling assessment of cohort-wide viral
suppression.
This study used recent data to explore temporal changes in
patient characteristics at enrolment and to describe long-term
mortality in patients initiating ART 2004–2015 in South African
sites of IeDEA-SA. Secondary objectives were to explore these
trends by gender relative to the HIV-negative population, and
to provide some assessment of viral suppression as a measure
of non-mortality outcomes.
Methods
Data sources
IeDEA-SA is a regional collaboration combining routine
observational data from large ART programmes in
Southern Africa. In South Africa, nine adult cohorts of
IeDEA-SA provide ART services in three of the most popu-
lous provinces (Gauteng, KwaZulu-Natal and Western
Cape). Cohorts range in size, are predominantly govern-
ment funded and follow national HIV treatment guidelines.
Patients are broadly representative of HIV-positive adults
accessing public sector ART in rural and urban centres [33].
This study was a cohort analysis of anonymized routine
data collected prospectively from five large South African
ART programmes which collect ID numbers: two in urban
primary healthcare clinics (Gugulethu and Khayelitsha), two
in urban hospitals (Themba Lethu and Tygerberg) and a
large rural cohort of 17 primary healthcare clinics (Hlabisa).
Eligibility criteria
We included ART-naïve adults 16–85 years old with
recorded ID numbers who started ART 2004 to 2015. The
analysis was limited to patients with ID numbers to ensure
the best possible mortality ascertainment. Patients were
followed from the date of ART initiation (regarded as base-
line) to analysis closure date, which was 30 days prior to
the date when site records were linked to the NPR, to make
provision for delays in reporting of deaths.
Outcomes
The primary outcome was all-cause mortality. Patients’ vital
status at analysis closure was confirmed by the South
African Medical Research Council through deterministic
linkage with recorded deaths on the NPR. In the case of
discrepancies between site- and NPR-recorded mortality,
we used the site-recorded date (for deaths that were not
recorded in the NPR) or the NPR date (for deaths recorded
in the NPR only, and deaths recorded in both sources but
with differing dates). All patients whose deaths were not
recorded prior to the analysis closure date (either on the
NPR or in site records), including those patients who sites
classified as transferred or lost to follow-up (LTF), were
recorded as alive at analysis closure.
Viral suppression among patients with VLs in their last
year of follow-up was the secondary outcome. According to
national guidelines, routine monitoring involves a VL test at
6 and 12 months on ART, and then every 12 months, with
more frequent monitoring of patients with unsuppressed
VLs [34]. We analysed the completeness of VLs in the last
year of patient follow-up and the percentages of patients
with suppressed VLs (measurement of less than
1000 copies/mL) by gender and calendar period of
enrolment.
Statistical analyses
Datawere cleaned, coded and analysed using the Stata package
(Version 13.1., College Station, TX, USA). Summary baseline
characteristics (gender, age, pregnancy, weight, CD4 continuous
and categorical, WHO stage and tuberculosis (TB) diagnosis)
were described using proportions, medians and interquartile
ranges (IQRs). We reported characteristics overall, by gender
and by calendar period of ART initiation in quartiles (2004–
2006, 2007–2009, 2010–2012 and 2013–2015), and compared
baseline characteristics of patients with and without IDs. The
number and proportion of deaths, median follow-up times and
mortality rates were reported by gender. Cumulative mortality
proportions and 95% confidence intervals (CIs) were presented
by calendar period and time since ART initiation, overall and by
gender.
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Crude mortality was compared by gender using the
Kaplan–Meier estimator. Cox’s proportional hazards models
were used to assess crude and adjusted associations
between patients’ characteristics and mortality. We
adjusted models for baseline characteristics (gender, age,
CD4 count, WHO stage, TB diagnosis, weight and site of ART
initiation) and calendar period of ART initiation. We
assumed that data were missing at random, mostly for
administrative and clerical reasons, and had no reason to
believe that unmeasured factors influenced the probability
of missingness. We used multiple imputation [35] with
chained equation methods [36] to impute missing baseline
covariates 10 times: CD4 count,WHO stage, TB (yes/no) and
weight. We evaluated the proportional hazard assumption
using “log–log” plots for all categorical variables in the
multiply imputed data sets. In all instances, the lines were
approximately parallel, thus the assumption did not seem
to be violated.
We calculated standardized mortality ratios (SMRs) by
dividing actual numbers of deaths in IeDEA-SA patients by
the numbers of deaths that would have been expected if all
patients were HIV negative [37]. HIV-negative mortality
rates, by age and gender, were set at the 2010 estimates
from Thembisa version 2.5, a combined demographic and
HIV model for South Africa [38]. We calculated actual and
expected numbers of deaths separately for different base-
line CD4 categories, for different times since first ART
initiation, and for men and women. CIs for the SMRs
were calculated on the assumption that the number of
deaths in each covariate category was Poisson-distributed.
Ethics and informed consent
All participating sites obtained ethics approval from rele-
vant local institutions before contributing anonymized
patient data to this collaborative analysis. Informed consent
was not required as data were not identifiable.
Results
Of 102,145 patients, 71% (n = 72,887) had IDs and were
eligible for inclusion. Of these, 75 patients were excluded
(date of death from the NPR prior to their recorded ART
initiation date). Overall, 72,812 patients were included in
the analysis.
Patients were predominantly female (n = 49,025, 67%)
and the proportion of males initiating treatment did not
increase over 12 years (Table 1). At ART initiation, men
were older than women (median 38 years, IQR 33–45 vs.
33 years, IQR 28–40). The median CD4 count increased in
successive calendar periods, from 101 cells/µL in
2004–2006 to 242 cells/µL in 2013–2015.
Men started ART with more severe disease progression
than women: compared with women, men had lower med-
ian CD4 counts (83 vs. 108 cells/µL in 2004–2006, 184 vs.
267 cells/µL in 2013–2015), were more likely to start ART
with a CD4 count <50 cells/µL (25% vs. 15%), less likely to
initiate treatment with a CD4 count ≥350 cells/µL (12% vs.
28% in 2013–2015) and more likely to have WHO Stage III
or IV at ART start. Twice the proportion of men compared
with women initiating ART in 2013–2015 had TB. The frac-
tion of women who were pregnant at ART initiation was
twice as high in the last quartile of enrolment as in the first
(16% vs. 8%). Patients with and without IDs were similar in
baseline characteristics (Supplementary Table 1).
Patients were followed for 350,376 pyrs, with a median
(IQR) follow-up of 4.48 (2.42–7.03) pyrs. The median follow-
up time was 1.28 (0.25–3.47) pyrs among patients who died
and 4.93 (3.08–7.41) pyrs among patients who were alive at
study end. Women were followed for longer than men:
median (IQR) 4.61 (2.55-7.17) vs. 4.24 (2.14-6.71) pyrs. At
analysis closure, 10,796 (15%) patients had died: 21%
(n = 4891) of male and 12% (n = 5905) of female patients.
The crude mortality rate was 3.08 (95% CI 3.02–3.14)/
100 pyrs; the rate among men was nearly double the rate
in women (4.50 [95% CI 4.38–4.63] vs. 2.44 [95% CI 2.38–
2.51]/100 pyrs).
Twelve years after ART initiation, cumulative mortality
was 23.9% (95% CI 22.8–25.1%), and higher among men
than women (33.4% vs. 19.4%) (Supplementary Table 2).
Mortality peaked in patients initiating treatment in
2007–2009 (Figure 1). In subsequent calendar periods of
ART initiation, mortality was lower at all durations.
Mortality was higher in men than women at all durations
and in all calendar periods of ART initiation.
Results of the SMR analysis are shown in Table 2.
Observed mortality was higher than HIV-negative age-stan-
dardized mortality in both men and women, particularly in
the first year since ART initiation. Observed mortality rates
dropped with duration since ART initiation, and by four
years, were close to those in the HIV-negative population.
Observed mortality rates also declined with increasing CD4
count at ART initiation, and by four years, SMRs were
similar for all baseline CD4 strata.
In univariate analysis, the risk of death was higher among
males and older patients, and among those with lower CD4
counts, higher WHO stage, TB, lower weight and earlier
calendar period of ART initiation (Table 3). In multivariable
analysis, most associations persisted but were attenuated,
with increased risk among patients who were male (aHR
1.41, 95% CI 1.36–1.47) and older (aHR 3.14, 95% CI 2.68–
3.67, patients 65 and older vs. 16–29 years), with lower
CD4 counts (aHR 0.40, 95% CI 0.38–0.44: CD ≥200 vs.
<50 cells/µL) and higher WHO stage (aHR 2.09, 95% CI
1.93–2.26, WHO stage IV vs. I and II). For every 10 kg
increase in weight at ART initiation, there was a 23%
decrease in mortality risk (aHR 0.77, 95% CI 0.76–0.79).
There was a modest decline in the risk of death in patients
initiating ART in 2013–2015 compared with 2004–2006
(aHR 0.85, 95% CI 0.78–0.92). After adjustment for other
variables, a TB diagnosis at ART initiation was associated
with a reduction in mortality risk (aHR 0.93, 95% CI
0.88–0.99).
Overall, 54,045 (74%) patients had VL measures in their
last year of follow-up (Table 4). Among patients with VLs,
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Table 1. Baseline characteristics of patients by calendar period of ART initiation and gender.
2004–2006
(n = 11,243)
2007–2009
(n = 19,148)
2010–2012
(n = 27,516)
2013–2015
(n = 14,905) Total (n = 72,812)
Gender, n (%)
Males 3537 (31%) 6531 (34%) 8974 (33%) 4745 (32%) 23,787 (33%)
Females 7706 (69%) 12,617 (66%) 18,542 (67%) 10,160 (68%) 49,025 (67%)
Age (years), median (IQR)
Males 37 (33–43) 38 (33–45) 38 (32–45) 38 (32–44) 38 (33–45)
Females 33 (29–39) 34 (28–40) 33 (28–41) 32 (27–39) 33 (28–40)
CD4 count (cells/µL) n (%)
Observations 9646 (86%) 17,259 (87%) 24,341 (83%) 12,788 (69%) 64,034 (82%)
Median (IQR)
All 101 (44–163) 120 (57–179) 166 (86–243) 242 (121–344) 148 (71–227)
Males 83 (33–149) 98 (42–164) 135 (61–212) 184 (81–296) 121 (51–197)
Females 108 (51–167) 132 (66–184) 179 (100–255) 267 (147–370) 161 (84–241)
0–49
All 2664 (28%) 3826 (22%) 3604 (15%) 1429 (11%) 11,523 (18%)
Males 1043 (34%) 1702 (29%) 1675 (21%) 674 (17%) 5094 (25%)
Females 1621 (24%) 2124 (19%) 1929 (12%) 755 (9%) 6429 (15%)
50–199
All 5983 (62%) 10,771 (62%) 11,556 (48%) 3829 (30%) 32,139 (51%)
Males 1720 (57%) 3530 (60%) 4002 (50%) 1545 (38%) 10,797 (52%)
Females 4263 (64%) 7241 (64%) 7554 (46%) 2284 (27%) 21,342 (51%)
200–349
All 898 (9%) 2363 (14%) 8149 (33%) 4510 (35%) 15,920 (24%)
Males 228 (8%) 611 (10%) 2018 (25%) 1348 (33%) 4205 (19%)
Females 670 (10%) 1752 (15%) 6131 (37%) 3162 (37%) 11,715 (27%)
≥350
All 104 (1%) 306 (2%) 1046 (4%) 3026 (23%) 4482 (7%)
Males 36 (1%) 73 (1%) 249 (3%) 543 (12%) 901 (4%)
Females 68 (1%) 233 (2%) 797 (5%) 2483 (28%) 3581 (7%)
WHO stage, n (%)
Observations 5529 (49%) 10,665 (56%) 17,264 (63%) 10,640 (72%) 44,098 (61%)
I and II
Males 273 (16%) 689 (19%) 2133 (39%) 1620 (52%) 4715 (34%)
Females 939 (24%) 2477 (35%) 7084 (60%) 5463 (73%) 15,963 (53%)
III
Males 930 (55%) 2149 (59%) 2366 (44%) 1172 (37%) 6617 (48%)
Females 1999 (52%) 3408 (48%) 3528 (30%) 1586 (21%) 10,521 (35%)
IV
Males 486 (29%) 783 (22%) 911 (17%) 339 (11%) 2519 (18%)
Females 902 (23%) 1159 (16%) 1242 (11%) 460 (6%) 3763 (12%)
TB diagnosis, n (%)
Observations 8766 (78%) 16,667 (87%) 21,957 (80%) 12,502 (84%) 59,892 (84%)
Males 861 (31%) 1779 (31%) 1864 (26%) 848 (20%) 5352 (27%)
Females 1319 (22%) 2263 (21%) 1946 (13%) 870 (10%) 6398 (16%)
Weight (kg), med (IQR)
Observations 7293 (65%) 14,086 (74%) 19,471 (71%) 9783 (66%) 50,633 (70%)
Males 61 (54–68) 60 (54–68) 62 (55–69) 63 (57–72) 61 (55–69)
Females 60 (52–69) 61 (53–71) 64 (55–76) 68 (58–81) 63 (54–75)
Pregnant females, n (%) 523 (8%) 915 (8%) 1620 (10%) 1449 (16%) 4507 (10%)
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86% (n = 46,675) were virally suppressed, with slightly
higher proportions among women compared to men in all
calendar periods of ART initiation.
Discussion
In this cohort of adults starting ART in South Africa with
near-complete ascertainment of deaths, three-quarters of
patients were alive twelve years after initiation of treat-
ment. Our findings provide reassurance that the national
ART programme is functioning effectively. Despite increased
enrolment, mortality was remarkably stable across calendar
periods and with duration on treatment. With increasing
duration on ART, SMRs and absolute mortality differences
compared to HIV-negative individuals declined. Markers of
disease severity at ART initiation improved, suggesting
improved coverage. High levels of viral suppression were
sustained over time, but gender disparities in ART initiation
and mortality persisted.
Despite a delayed start, the South African ART pro-
gramme has expanded ART services enormously since its
inception in 2004, increasing enrolment each successive
year. Concurrently, the entire national health system has
undergone major restructuring to a district health system
implementing primary healthcare, placing additional strain
on an already heavily burdened health system [39]. Despite
these challenges, 74% of patients were still alive twelve
years after starting treatment, suggesting that early fears
of “antiretroviral anarchy” in Africa [40] were unfounded.
Numerous studies over the past ten years have
addressed the complex issue of mortality estimation,
particularly in developing countries [41–46]. Many coun-
tries with large, rapidly expanding ART programmes lack
functioning vital registration systems, and mortality
ascertainment from standard patients’ record systems
may misclassify a high proportion of deaths as LTF
[12,41]. To correct for mortality among patients LTF,
different approaches have been used including tracing
studies [47–49] and the application of a nomogram
[44]. However, using different methods of mortality
ascertainment can impact on mortality estimates. In our
study, linkage of patient records to the well-functioning
NPR has ensured that all patients have known outcomes
at analysis closure, including those who were LTF or
transferred. It is thus unsurprising that our mortality
estimates are higher than long-term reports from other
large national ART programmes which rely on passive
mortality ascertainment and report high rates of LTF.
For example, among 226,030 patients who started ART
in the Botswana national programme between 2002 and
2013, the reported mortality rate was lower than in our
study (2.06/100 vs. 3.10/100 pyrs), while the rate of LTF
was high (12.47/100 pyrs) [50]. Studies which compare
and combine mortality data must thus consider the pos-
sible impact of differential mortality ascertainment on
their estimates.
Mortality estimates from ART programmes also rarely
include a comparison with HIV-negative mortality rates.
Using age-standardization, we were able to compare
observed mortality with rates in the HIV-negative popula-
tion. Observed mortality was far higher than in the HIV-
negative population, particularly in the first year after ART
initiation. By four years after ART initiation, SMRs were
similar in all CD4 strata, suggesting that baseline immuno-
logic status no longer impacted mortality rates substan-
tially. Due to far higher background mortality rates in men
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Figure 1. Cumulative mortality by calendar period of ART initiation and duration, by gender.
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Table 2. Observed mortality rates (per 100 person-years) and standardized mortality ratios (SMRs)a by gender, duration since ART initiation and CD4 count at ART initiationb.
Males Females
Duration since ART initiation (months) Duration since ART initiation (months)
0–12 12–24 24–48 >48 0–12 12–24 24–48 >48
CD4 count <50 cells/µL
Observed mortality (crude) 19.54 5.55 4.07 2.69 16.93 4.26 2.55 1.66
Observed deaths 865 215 265 242 961 217 227 233
HIV-negative mortality (age standardized) 0.78 0.82 0.89 1.05 0.36 0.38 0.41 0.48
SMR 24.98 6.76 4.57 2.57 46.71 11.36 6.27 3.46
SMR 95% CI 23.31–26.64 5.86–7.67 4.02–5.12 2.25–2.9 43.76–49.67 9.84–12.87 5.46–7.09 3.02–3.91
CD4 count 50–199 cells/µL
Observed mortality (crude) 8.65 3.67 3.17 2.84 5.33 2.08 1.65 1.44
Observed deaths 871 336 494 545 1088 399 566 697
HIV-negative mortality (age standardized) 0.86 0.90 0.97 1.12 0.38 0.40 0.43 0.50
SMR 10.01 4.06 3.27 2.53 13.91 5.21 3.83 2.90
SMR 95% CI 9.35–10.68 3.62–4.49 2.98–3.56 2.32–2.74 13.09–14.74 4.7–5.72 3.52–4.15 2.69–3.12
CD4 count ≥200 cells/µL
Observed mortality (crude) 4.01 2.65 2.04 2.11 2.46 1.27 1.15 1.13
Observed deaths 191 104 115 81 357 154 202 143
HIV-negative mortality (age standardized) 0.85 0.88 0.95 1.10 0.37 0.38 0.42 0.47
SMR 4.73 3.01 2.15 1.92 6.74 3.31 2.76 2.39
SMR 95% CI 4.06–5.4 2.43–3.58 1.76–2.54 1.5–2.34 6.04–7.44 2.79–3.83 2.38–3.14 2.0–2.78
aSMR: The number of observed deaths divided by the number of deaths expected if all patients were HIV negative.
bExcludes 1228 patients who had no CD4 count at ART initiation.
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compared with women, female SMRs were higher than
male, even though all-cause mortality rates in men were
higher than those in women. SMRs declined towards 1 as
ART duration increased, suggesting an increasing “normal-
ization” of mortality in ART patients with duration on treat-
ment [51,52]. Our results highlight the need to assess and
compare mortality estimates in ART programmes in the
context of background mortality.
The steady increase in median CD4 count in successive
calendar periods of ART initiation reflects improved cover-
age, as the programme progressed from initiating only the
sickest patients. In a previous study, the median CD4 count
at ART initiation increased worldwide between 2000 and
2009 but remained <200 cells/µL in low- and middle-
income countries including South Africa [53]. We demon-
strated a sustained increase in successive calendar periods,
reaching 242 cells/µL in patients enrolled in 2013–2015,
nearly 2.5 times that in the earliest enrolled patients.
With the introduction of universal eligibility for ART, base-
line CD4 counts should continue to increase.
However, it appears that increasing CD4 count at enrol-
ment did not always result in decreasing first-year mortal-
ity. In these cohorts, after adjusting for baseline CD4 count,
first-year mortality continued to rise over the first few years
of ART, only decreasing after 2009 (Supplementary
Table 3). It is likely that the rapid scale-up of the pro-
gramme and the contribution of different cohorts contrib-
uted to the increasing mortality up to 2009. In our analysis,
we did not focus on differences between sites of ART
initiation; however, there were differences (numbers
enrolled and mortality estimates) between hospital and
primary care cohorts, and between urban and rural
cohorts. It is plausible that the differential contribution of
cohorts over time partially explains the failure to see an
initial decline in early mortality.
The apparently protective effect of TB at ART initiation
has been previously observed [8] and may be related to the
close case-holding that happens in coinfected patients who
need to attend the clinic far more regularly than patients
who are not coinfected. It could also be related to the fact
that in patients with TB at ART initiation, the TB is identified
and treated, whereas unrecognized TB is postulated to be a
large contributor to early mortality.
As services expand further, high levels of viral suppres-
sion must be maintained. The national ART guidelines
recommend VL testing as the “preferred approach for mon-
itoring ART success and diagnosing treatment failure” [34].
Despite increasing patient numbers, 74% of all patients in
these cohorts had a VL measured in their last year of
follow-up. It is reassuring that 86% of these patients were
virally suppressed, close to the UNAIDS target of 90% sup-
pression. This compares well with national and global fig-
ures. In 2015, 78.4% of patients on ART tested nationwide
had undetectable VLs, and at a threshold of 1000 copies/
mL, this fraction would be 81.7% [2]. Ongoing monitoring is
required to ensure that high levels of suppression are
sustained.
We found evidence that programmes to prevent mother-
to-child transmission of HIV (PMTCT) may have increased ART
initiation in pregnant women. PMTCT guidelines have evolved
over the years, increasing pregnant women’s access to HIV
testing and ART. Option B, introduced in 2013 [54], recom-
mended ART for themother from 14-weeks gestation through
to birth or the end of breastfeeding, while Option B+, intro-
duced in 2015 [34], advocated lifelong ART for the mother.
National ART guidelines also recommend routine HIV testing
as part of clinical care and screening for pregnant and breast-
feeding women: testing every three months throughout preg-
nancy, at labour/delivery, at the 6-week immunization visit,
and every three months throughout breastfeeding [34].
Women who choose not to be tested must be provided with
Table 3. Crude and adjusteda associations with mortality.
Mortality
Univariate
HR (95% CI)
Multivariable
aHR (95% CI)
Gender, male 1.80 (1.74–1.87) 1.41 (1.36–1.47)
Age (years)
16–29 1 1
30–34 1.14 (1.07–1.21) 1.04 (0.98–1.11)
35–39 1.28 (1.20–1.35) 1.12 (1.05–1.19)
40–44 1.46 (1.37–1.56) 1.28 (1.20–1.37)
45–49 1.60 (1.49–1.72) 1.40 (1.30–1.51)
50–54 1.93 (1.79–2.11) 1.71 (1.57–1.86)
55–59 2.38 (2.18–2.66) 2.10 (1.90–2.33)
60–64 3.02 (2.68–3.53) 2.63 (2.28–3.04)
65+ 3.87 (3.35–4.55) 3.14 (2.68–3.67)
CD4 count (cells/µL)
<50 1 1
50–99 0.69 (0.65–0.73) 0.74 (0.70–0.79)
100–199 0.45 (0.44–0.49) 0.56 (0.54–0.60)
≥200 0.26 (0.25–0.29) 0.40 (0.38–0.44)
WHO stage
I and II 1 1
III 2.24 (2.12–2.37) 1.55 (1.46–1.66)
IV 3.26 (3.04–3.48) 2.09 (1.93–2.26)
TB diagnosis 1.62 (1.55–1.70) 0.93 (0.88–0.99)
Weight, 10 kg 0.71 (0.69–0.72) 0.77 (0.76–0.79)
Year ART initiated
2004–2006 1 1
2007–2009 1.00 (0.95–1.05) 1.03 (0.98–1.14)
2010–2012 0.73 (0.69–0.77) 0.98 (0.92–1.03)
2013–2015 0.47 (0.44–0.51) 0.85 (0.78–0.92)
Site of ART initiation
Cohort 1 1 1
Cohort 2 2.07 (1.88–2.28) 1.91 (1.73–2.11)
Cohort 3 1.38 (1.25–1.53) 1.36 (1.22–1.51)
Cohort 4 1.72 (1.56–1.90) 1.46 (1.31–1.62)
Cohort 5 2.35 (2.09–2.64) 1.83 (1.62–2.07)
aAfter multiple imputation.
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“post-refusal” counselling and then offered testing again at all
subsequent visits. We found that these guidelines increased
ART initiation among pregnant women: the proportion of
women who were pregnant at ART initiation doubled, with
most of the increase in patients enrolled in 2013–2015. During
the same time period, the proportion of women starting ART
with CD4 ≥350 cells/µL was twice that among men.
Unfortunately, South African ART programmes have had
less success in ensuring equitable access to ART for men.
Despite overwhelming evidence of men’s poorer access to
HIV testing [25,27] and ART initiation [23,24,26,55,56], men
still started ART at older ages and with more advanced HIV
disease than women in all calendar periods. Furthermore, the
proportion of men starting ART did not increase over twelve
years. This is in line with findings from a large national study
by the NHLS which analysed nearly 4 million CD4 count and VL
measurements from 2012 to estimate progress towards the
UNAIDS 90:90:90 targets []. At each stage of the ART cascade,
men had poorer engagement than women [57]. With the
implementation of Option B+, it is possible that such gender
disparities in access to ART may increase, as has been
reported in Malawi [58] and Mozambique [3]. National cam-
paigns are urgently needed to increase testing and earlier ART
initiation among men.
This study was strengthened by the large sample size, the
duration of follow-up, the comparison with HIV-negative
mortality and, in particular, by linkage to the NPR allowing
accurate ascertainment of mortality. Interpretation of these
results has several limitations. First, these data from predo-
minantly urban research cohorts may not represent all public
sector ART cohorts; hence, these results may not be general-
izable in all settings. Second, as these are observational data,
a proportion of data were missing for most baseline
variables, a limitation we addressed through the use of
multiple imputation. Third, notwithstanding the similar base-
line characteristics reported between patients with and with-
out IDs, if these patient groups differed in unmeasured ways,
our findings could be biased. Similarly, VL assessments were
not available for a quarter of patients in their last year of
follow-up, which might bias our assessment of viral suppres-
sion. However, in analysis restricted to patients who had VLs
measured at any timepoint, there was little difference in the
proportions virally suppressed at their last VL measurement,
comparing those with and without a VL in their last year of
follow-up (86% vs. 83%) (Supplementary Table 4). Finally, our
available measures of disease severity used to adjust our
analyses might not fully capture the improving clinical status
at ART initiation over time.
In conclusion, the South African ART programme has
demonstrated a remarkable ability to initiate and manage
patients successfully over twelve years, despite rapidly expand-
ing patient numbers. As the country scales up services to treat
the roughly 3 million individuals still requiring ART in 2017,
testing and initiating men on ART must be a national priority.
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